{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002727","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2026-05-15T12:00:26+00:00","discovered_at":"2026-05-15T12:05:00.218088+00:00","generated_at":"2026-05-15T12:07:11.452653+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M","bullets":["Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.","Net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) in Q1 2025; one-time $4.9M R&D charge.","Unrestricted cash $11.4M at Mar 31, 2026, up from $2.2M at Dec 31, 2025; $6.5M from Oratech.","Operating cash burn improved 33% YoY to $3.7M; ReWalk exoskeleton sales up 11% to $1.6M.","Strategic transaction closed: $10M financing, Oratech acquisition with oral insulin Phase 2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002727","json":"https://secwatch.observer/filing/0001178913-26-002727.json","markdown":"https://secwatch.observer/filing/0001178913-26-002727.md","text":"https://secwatch.observer/filing/0001178913-26-002727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/0001178913-26-002727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/zk2635349.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:07:11.452653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}